
|Articles|December 17, 2008
Novel conjunctivitis drug recommended by FDA
Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.
Advertisement
Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.
Besifloxacin, a broad-spectrum fluoroquinolone anti-microbial agent, works by inhibiting inflammation in THP-1 monocytes.
The FDA recommendation is a step towards final approval; if approved, Bausch & Lomb aims to bring besifloxacin to the market next year.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD
3
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
4
Think outside the cone: Applying the Gulani Keratoconus Classification
5


















